Re-establishing self-tolerance by targeting MHC class II-restricted autoimmunity

Juvenile diabetes is an autoimmune disease resulting from an attack that destroys pancreatic cells that secrete insulin. Javier Clemente Casares is studying a therapeutic approach that could lead to a nanovaccine for the disease.

A nanovaccine for juvenile diabetes

To add or modify information on this page, please contact us at the following address: community.research@axa.com

Javier
CLEMENTE-CASARES

Institution

University of Calgary

Country

Canada

Nationality

Spanish

Health

Chronic & Non-communicable Diseases

Medical Treatment & Drug Development

Chronic Pain & Musculoskeletal Disorders

Drug Delivery

Biotech- and Nanotechnology

AXA Project

France

Pain Pediatric & Elderly AXA Research Lab (PEARL)

Chronic pain is recognized as a major public health problem affecting patients in their daily activity, physical and mental health,... Read more

Celine
GRECO

Hôpital Necker-Enfants Malades

Health

Medical Treatment & Drug Development

Drug Delivery

Biotech- and Nanotechnology

Mécénat des Mutuelle

France

Accelerating drug innovation with the Euridis school and its DDD Challenge

The project addresses a dual challenge: on one hand, the increasing complexity of drug development, which requires a thorough understanding... Read more